Can Truecaller’s (OM:TRUE B) New Family Protection Tools Deepen Its Subscription and Engagement Moat?

• Earlier in December 2025, Truecaller launched Family Protection, a new in-app feature that lets up to five users form trusted groups where a Family Admin can set protection levels, manage blocklists, and on Android even remotely end suspected scam calls while monitoring real-time status signals.
• This move deepens Truecaller’s role in everyday communication safety, creating a shared protection layer that could strengthen engagement and support migration toward its Premium Family subscription offering.
• We’ll now examine how Family Protection’s group-based safety tools may influence Truecaller’s investment narrative around recurring subscriptions and user stickiness.

These 10 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Truecaller Investment Narrative Recap

To own Truecaller, you need to believe it can convert its large communication-safety user base into growing, recurring subscription revenue while reducing reliance on volatile programmatic ad income. The Family Protection launch supports that subscription narrative but does not materially change the near term risk that weaker ad demand and partner dependence in India could still drive earnings swings, especially when combined with FX and tax headwinds.

The most relevant recent development alongside Family Protection is Truecaller’s ongoing share buyback program, which is active through the 2026 AGM and can cover up to 10% of shares. While buybacks can support per share metrics during periods of ad revenue softness, the key near term catalyst still sits with how quickly higher quality, recurring revenues like subscriptions and Truecaller for Business can grow as a counterweight.

Yet behind these product launches and capital returns, investors should be aware that dependence on third party ad platforms in India still leaves Truecaller exposed to ...

Read the full narrative on Truecaller (it's free!)

Truecaller's narrative projects SEK3.5 billion revenue and SEK1.1 billion earnings by 2028. This requires 20.2% yearly revenue growth and an earnings increase of about SEK612 million from SEK488.0 million today.

Uncover how Truecaller's forecasts yield a SEK50.83 fair value, a 175% upside to its current price.

Exploring Other Perspectives

Eleven members of the Simply Wall St Community value Truecaller between SEK36.57 and SEK105.06, highlighting very different expectations around its potential. Against this wide spread, the heavy concentration of ad revenues in India and on external platforms raises important questions about how resilient those expectations really are, so it is worth comparing several of these viewpoints before forming a view.

Explore 11 other fair value estimates on Truecaller - why the stock might be worth over 5x more than the current price!

Build Your Own Truecaller Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Truecaller research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Truecaller research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Truecaller's overall financial health at a glance.

Seeking Other Investments?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are the new gold rush. Find out which 33 stocks are leading the charge.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com